4 October 2023 in Biomacromolecules
Thiol-reactive Michael acceptors are commonly used for the formation of chemically cross-linked hydrogels. In this paper, we address the drawbacks of many Michael acceptors by introducing pyridazinediones as new cross-linking agents. Through the use of pyridazinediones and their mono- or dibrominated analogues, we show that the mechanical strength, swelling ratio, and rate of gelation can all be controlled in a pH-sensitive manner. Moreover, we demonstrate that the degradation of pyridazinedione-gels can be induced by the addition of thiols, thus providing a route to responsive or dynamic gels, and that monobromo-pyridazinedione gels are able to support the proliferation of human cells. We anticipate that our results will provide a valuable and complementary addition to the existing toolkit of cross-linking agents, allowing researchers to tune and rationally design the properties of biomedical hydrogels.
14 November 2023 in Bioconjugate Chemistry
Bispecific antibodies as T cell engagers designed to display binding capabilities to both tumor-associated antigens and antigens on T cells are considered promising agents in the fight against cancer. Even though chemical strategies to develop such constructs have emerged, a method that readily converts a therapeutically applied antibody into a bispecific construct by a fully non-genetic process is not yet available. Herein, we report the application of a biogenic, tyrosine-based click reaction utilizing chemoenzymatic modifications of native IgG1 antibodies to generate a synthetic bispecific antibody construct that exhibits tumor-killing capability at picomolar concentrations. Control experiments revealed that a covalent linkage of the different components is required for the observed biological activities. In view of the highly potent nature of the constructs and the modular approach that relies on convenient synthetic methods utilizing therapeutically approved biomolecules, our method expedites the production of potent bispecific antibody constructs with tunable cell killing efficacy with significant impact on therapeutic properties.
6 January 2025 in Chemical Science
Exploiting quantitative and reversible site-selective disulfide modification as a means for selective lysine functionalisation on clinically relevant antibody fragments.
16 September 2024 in Bioconjugate Chemistry
Redirecting T cells to tumor cells by bispecific antibodies is an effective approach to treat cancer, and T cell-dependent bispecific antibodies (TDBAs) are an emerging class of potent immunotherapeutic agents. By simultaneously targeting antigens on tumor cells and T cells, T cells are activated to kill tumor cells. Herein, we report a platform to generate a novel class of 2:1 structure of T cell-dependent bispecific antibody with bivalency for HER2 receptors on tumor cells and monovalency for CD3 receptors on T cells. For this, we use a biogenic inverse electron-demand Diels-Alder (IEDDA) click reaction on genetically encoded tyrosine residues to install one TCO handle on therapeutically approved antibody trastuzumab. Subsequent TCO-tetrazine click with a tetrazine-functionalized CD3-binding Fab yields a 2:1 HER2 × CD3 TDBA that exhibits a tumor-killing capability at picomolar concentrations. Monovalency toward the CD3 receptor on T cells can lower the chances of cytokine release syndrome, which is a common side effect of such agents. Our semisynthetic approach can generate highly potent TDBA constructs in a few chemoenzymatic and synthetic steps.
13 November 2026 in bioRxiv
Cyclin-dependent kinase 12 (CDK12) is an attractive therapeutic target due to its critical role in transcriptional regulation and DNA damage response and is frequently co-amplified with ERBB2 (HER2) in breast cancer. CDK12 forms an active complex with its obligate partner cyclin K (CCNK), and pharmacological degradation of CCNK has emerged as a promising strategy for disrupting CDK12-dependent transcriptional programs. However, the broad expression and essential functions of the CDK12/CCNK complex may limit the therapeutic window of highly potent molecular glue degraders. Here, we investigate whether antibody-mediated delivery can impart cellular selectivity to a molecular glue degrader through targeting the HER2 receptor. Molecular glues lack the modular architecture of PROTACs, thus linker placement can be the central design problem. We designed SAS1001, a CCNK molecular glue degrader with a solvent-exposed piperazine primed for linker attachment. SAS1001 induced potent and ubiquitin-proteasome system-dependent degradation of CCNK and inhibited proliferation in a range of breast cancer cells. Conjugation to trastuzumab (Tz) generated the HER2-targeted degrader-antibody conjugate Tz-SS2009, which internalized preferentially in HER2-positive cells and produced enhanced CCNK degradation and antiproliferative effects, relative both to HER2-negative cells and to an isotype-matched non-targeting conjugate. Whole proteome analysis further demonstrated CCNK depletion and revealed downstream changes consistent with established roles of the CDK12/CCNK complex in transcriptional regulation. These findings demonstrate that antibody-mediated delivery can redistribute the cellular activity of a potent molecular glue degrader towards antigen-positive cells. In the CR8/DS18 purine series, substitution at a solvent-exposed position preserved CCNK degradation when the degrader was delivered on a full-length IgG. More broadly, this work extends antibody-directed degradation beyond the CRBN-based glues that have dominated the field and illustrates how structural characterization of a glue scaffold can identify a linker attachment point that does not compromise activity.